...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Financials

"Bear I was referring to Zenith's Web Home Page."

Regardless of whether you are referring to Zenith's webpage or to SEDAR, the fact remains that the MD&A and financials for the period endings April 30th and July 31st are filed in late August and September, respectively, according to the pattern the last few years. There is no evidence that Zenith's filing pattern has change this year compare to previous years.

BDAZ

Share
New Message
Please login to post a reply